Yumanity Therapeutics Inc expected to post a loss of 83  cents a share - Earnings Preview

Kineta

11/05/2021 21:26

* Yumanity Therapeutics Inc  YMTX.OQ   YMTX.O  is expected
to show a rise in quarterly revenue when it reports results on
May 13 (estimated) .
* The Boston, Massachusetts-based company is expected to report
revenue of $500 thousand, according to the mean estimate from 2
analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for Yumanity Therapeutics
Inc is for a loss of 83 cents per share. For the same quarter
last year, the company reported a loss of $3.80 per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Yumanity
Therapeutics Inc is $36​, about 59.9% above​ its last closing
price of $14.42. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020              -2.80      3.96      Beat    241.4
 Sep. 30 2020  -3.48       -3.60      -2.20     Beat    38.9
 Jun. 30 2020  -4.27       -4.25      -3.40     Beat    20​
 Mar. 31 2020  -5.34       -5.10      -3.80     Beat    25.5
 Dec.          -5.09​      -5.75      -4.60     Beat    20​
 31​ 2019​                                              
 Sep. 30 2019  -8.12       -8.10      -5.00     Beat    38.3​
 Jun. 30 2019  -7.59       -7.53      -7.80     Missed  -3.5
 Mar. 31 2019  -7.32       -7.85      -5.60     Beat    28.7
 This summary was machine generated May 11 at 20:26 GMT.  All
figures in US dollars unless otherwise stated